| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_213e7b98bce3a9d6be9936049694fa1a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate |
2006-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9c69b9d3fd0772923da25247691ce5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afab946a9466d869bb1394875d4493e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8c89ebbf1adfbe42faf898b930ffcc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac74bc662f0b50e93d4dc01d2a18105a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dee118fdc404f2f2ea6582ec45746bbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_116eabc4d683a48754426a3e7c378c2f |
| publicationDate |
2011-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8012973-B2 |
| titleOfInvention |
Compounds for the treatment of auricular fibrillation |
| abstract |
Adenosine A 2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A 2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A 2A antagonists over other agents known in the art is that the A 2A antagonists specifically target patients with atrial fibrillation. |
| priorityDate |
2005-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |